Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
J Biomed Biotechnol. 2010;2010:465898. doi: 10.1155/2010/465898. Epub 2010 Jun 22.

Anti-TNF-alpha therapies in systemic lupus erythematosus.

Author information

  • 1Department of Nephrology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

Abstract

Tumor necrosis factor (TNF)-alpha is not just a proinflammatory cytokine. It has also been proposed to be an immunoregulatory molecule that can alter the balance of T regulatory cells. Anti-TNF-alpha therapies have been provided clinical benefit to many patients and introduced for treating moderate to severe rheumatoid arthritis, Crohn's disease, and other chronic inflammatory disorders. However, their use also is accompanied by new or aggravated forms of autoimmunity, such as formation of autoantibodies, including antinuclear antibodies (ANAs), antidouble-stranded DNA (dsDNA) antibodies, and anticardiolipin antibodies (ACL). Systemic lupus erythematosus (SLE) is a disease with autoimmune disturbance and inflammatory damage. The role of TNF-alpha in human SLE is controversial. Here we review the role of TNF-alpha in the pathophysiological processes of SLE and the likely effects of blocking TNF-alpha in treatment of SLE.

PMID:
20625488
[PubMed - indexed for MEDLINE]
PMCID:
PMC2896679
Free PMC Article

Images from this publication.See all images (1)Free text

Figure 1
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Hindawi Publishing Corporation Icon for PubMed Central
    Loading ...
    Write to the Help Desk